The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
PD-1 和 LAG-3 靶向双特异性分子替博替利单抗在实体瘤和血液系统癌症中的应用:1 期临床试验
期刊:Nature Medicine
影响因子:58.7
doi:10.1038/s41591-023-02593-0
Jason J Luke, Manish R Patel, George R Blumenschein, Erika Hamilton, Bartosz Chmielowski, Susanna V Ulahannan, Roisin M Connolly, Cesar A Santa-Maria, Jie Wang, Shakeela W Bahadur, Andrew Weickhardt, Adam S Asch, Girish Mallesara, Philip Clingan, Monika Dlugosz-Danecka, Monika Tomaszewska-Kiecana, H